Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001415889-24-029910
Filing Date
2024-12-19
Accepted
2024-12-19 18:09:43
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 21041
2 JOINT FILING AGREEMENT ex-99-12192024_111247.htm EX-99.1 6650
3 STOCK SALE PLAN ex-99-12192024_111249.htm EX-99.2 26003
  Complete submission text file 0001415889-24-029910.txt   55696
Mailing Address 11250 EL CAMINO REAL, SUITE 100 SAN DIEGO CA 92130
Business Address 11250 EL CAMINO REAL, SUITE 100 SAN DIEGO CA 92130 (858) 410-0266
Skye Bioscience, Inc. (Subject) CIK: 0001516551 (see all company filings)

EIN.: 450692882 | State of Incorp.: NV | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-87830 | Film No.: 241564591
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 4 EMBARCADERO CENTER, SUITE 3110 SAN FRANCISCO CA 94111
Business Address 4 EMBARCADERO CENTER, SUITE 3110 SAN FRANCISCO CA 94111 (415) 993-8565
5AM Partners VII, LLC (Filed by) CIK: 0001873545 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A